1st Jun 2026 15:00
Avacta Group plc
Block Listing Application to AIM
LONDON and PHILADELPHIA - June 1, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announces an application has been made to AIM for a block listing of 5,500,000 ordinary shares of 10 pence each in the Company ("Ordinary Shares"). This will be used to facilitate the admission of shares to trading following the exercise of options granted under the Group's LTIP/ESOS Scheme.
The Ordinary Shares will be issued from time to time pursuant to the Company's existing plans including outstanding options already issued but not yet exercised to the employees of the Company. New Ordinary Shares issued following option exercises and admitted to trading under the block admission will rank pari passu in all respects with the existing Ordinary Shares.
The block listing is expected to become effective on 2 June 2026. The Company will continue to make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.
At the time of this announcement, Avacta has 457,892,574 Ordinary Shares in issue. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
-Ends-
For further information from Avacta, please contact:
Avacta Group plc Christina Coughlin, Chief Executive Officer | https://avacta.com/ via Cohesion Bureau |
Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance
| www.strandhanson.co.uk
|
Zeus (Broker) James Hornigold / George Duxberry / Dominic King
| www.zeuscapital.co.uk |
Cohesion Bureau Communications / Media / Investors Richard Jarvis
|
|
About Avacta - https://avacta.com/
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDCs) leverage this tumor-specific release mechanism to provide unique benefits over traditional antibody drug conjugates, releasing active payload in the tumor and reducing systemic exposure and toxicity and allowing dosing to be optimized to deliver the best outcomes for patients.
Related Shares:
Avacta Group